Status:
COMPLETED
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Lead Sponsor:
Idera Pharmaceuticals, Inc.
Conditions:
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard weight based ribavirin (investigational treatment arm) or place...
Detailed Description
This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard ribavirin or placebo plus ribavirin. Each cohort will...
Eligibility Criteria
Inclusion
- Documented genotype 1
- HCV-positive with documented detectable plasma viral concentration \> 10,000 IU/mL
Exclusion
- Positive test for HIV or HbsAg
- Inadequate bone marrow, liver, and renal function
- Treatment with any IFN-based or other experimental or antiviral therapies - prior or current
- Other significant medical disease
- Concurrent or planned treatment during the study
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00990938
Start Date
September 1 2009
End Date
January 1 2011
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rennes, France, 35000